MeiraGTx Holdings Earnings Call Transcripts
Fiscal Year 2026
-
Three-year phase I data for AAV-AQP1 in persistent RIX show robust, durable efficacy and safety, with transformative, disease-modifying effects and high physician and payer support. The therapy targets a large, concentrated market, with pivotal data and BLA filing expected in 2027 and a U.S. launch in 2028.
-
The company highlighted late-stage ophthalmology programs for inherited retinal diseases, leveraging advanced gene therapy platforms and strong KOL relationships. Key partnerships with J&J and Lilly are advancing global filings, while a deep pipeline and innovative manufacturing support expansion into both rare and large indications.
Fiscal Year 2025
-
Gene therapy programs for neurodegenerative diseases are advancing, with local delivery and AI-driven analytics addressing key challenges in efficacy, safety, and patient heterogeneity. Regulatory agencies are increasingly flexible, and strong clinical data is expected to drive adoption.
-
The conference highlighted a robust gene therapy pipeline focused on local delivery, with transformative clinical data in rare pediatric blindness, ongoing pivotal trials in xerostomia and Parkinson's, and strong regulatory momentum. AI partnerships and internal manufacturing drive innovation and cost efficiency.
-
AAV-AIPL1 gene therapy in 11 children with severe congenital blindness led to dramatic, durable improvements in vision and quality of life, with no safety concerns. Regulatory agencies are considering expedited approval based on these results.
Fiscal Year 2024
-
The conference highlighted a robust pipeline with late-stage programs in ophthalmology, metabolic disease, xerostomia, and Parkinson's, all supported by advanced in-house manufacturing. The Riboswitch platform enables oral control of protein expression, with transformative potential for biologics and cell therapy.
-
Streamlined to focus on two late-stage programs, the company leverages proprietary riboswitch technology and advanced manufacturing to address large unmet needs in xerostomia and Parkinson's. Precise gene control enables superior efficacy in metabolic and cell therapy indications.